Abstract Changes occurring in host-associated microbial communities (ie, the microbiota)
may modulate responses to checkpoint blockade immunotherapy. We previously showed
that anti-programmed cell death protein 1, pembrolizumab, plus microtubule-targeting
chemotherapy, eribulin, has encouraging antitumor activity in previously pre-treated
hormone receptor (HR)-positive/human epidermal growth factor receptor 2-negative
metastatic breast cancer patients in the KELLY phase II study (NCT03222856). Faecal (58) …

Aim: Changes in host-associated microbial communities (ie, the microbiota) may modulate
responses to checkpoint blockade immunotherapy. In the KELLY phase II study
(NCT03222856), we previously demonstrated that pembrolizumab [anti-programmed cell
death protein 1 (PD-1)] combined with eribulin (plus microtubule-targeting chemotherapy)
showed encouraging antitumor activity in patients with hormone receptor (HR)-
positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast …